Yearly incidence of IPD.

<p>IPD yearly incidence per 100,000 population pre-vaccination (0 years) and after 10 and 40 years post-PCV13 with the competition parameter c_N = 0.04. Abbreviations: c_N, competition parameter; IPD, invasive pneumococcal disease; NVT, non-vaccine types; PCV13, 13-valent pneumococcal conjugate vaccine; VT, vaccine types.</p

Model parameters and ranges for the analysis of PCV13 in the Netherlands.

a<p>We used the same degree of protection for PCV13 that was estimated by Choi <i>et al</i> (2011) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0089415#pone.0089415-Choi1" target="_blank">[32]</a> for PCV7. Sensitivity analysis was done on this value.</p><p>Abbreviations: NVT, non-vaccine types; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; RIVM, National Institute for Public Health and the Environment, Ministry of Health, Welfare and Sport; VT, vaccine types.</p

Yearly incidence of IPD with different mixing parameters.

<p><b>A</b>, IPD incidence, VT; <b>B</b>, IPD incidence, NVT; and <b>C</b>, IPD overall incidence. Yearly incidence per 100,000 population over time when different mixing parameters are used: ε = 0.50, 0.85, 1.00; and the competition parameter is c_N = 0.04. Each panel corresponds to a different age group. Note: the y-axis scales are different on each graph. Abbreviations: c_N, competition parameter; ε, mixing paremeter; IPD, invasive pneumococcal disease; NVT, non-vaccine types; VT, vaccine types.</p

Carriage pre-PCV13.

<p>Estimated and observed carriage pre-PCV13. Prevalence rates are reported per each age or age group. Note that only the data points in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0089415#pone-0089415-g003" target="_blank">Figure 3</a> at ages 1 and 2 years, and age group 30–39 years correspond to observed carriage data; other points were interpolated. Abbreviations: c_N, competition parameter; NVT, non-vaccine types; PCV13, 13-valent pneumococcal conjugate vaccine; VT, vaccine types.</p

Dynamic transmission model.

<p>Flowchart representing the dynamic mathematical model used for the transmission. Abbreviations:γ_i, degree of protection; λ_N, age-dependent forces of infection for non-vaccine types; λ_V, age-dependent forces of infection for vaccine types; ωi, the waning rate; B, both vaccine types and non-vaccine types co-colonised; Bv, both vaccine types and non-vaccine types co-colonised with vaccination; c_N, competition parameters that determined the relative risk of acquiring non-vaccine types if already colonised by vaccine types; c_V, competition parameters that determined the relative risk of acquiring vaccine types if already colonised by non-vaccine types; i, age group; N, non-vaccine types carriers; Nv, non-vaccine types carriers with vaccination; r_N, recovery rate for non-vaccine types; r_V, recovery rate for vaccine types; S, susceptible; Sv, susceptible with vaccination; v, vaccination coverage; V, vaccine type carriers; Vv, vaccine types carriers with vaccination.</p

Additional file 1: Table S1. of Rates of pneumonia among children and adults with chronic medical conditions in Germany

Diagnosis, procedure, and drug codes for algorithms identifying at-risk conditions. (DOC 91 kb

Additional file 4: Table S4. of Rates of pneumonia among children and adults with chronic medical conditions in Germany

Rates of all-cause pneumonia among healthy, at-risk, and high-risk adults, by age. (DOC 941 kb

Additional file 2: Table S2. of Rates of pneumonia among children and adults with chronic medical conditions in Germany

High risk-conditions: Diagnosis, procedure, and drug codes for algorithms identifying baseline risk factors and study measures. (DOC 70 kb